Meletios A. Dimopoulos

A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

2015 | 1. lékařská fakulta

Publikace